Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 6/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605134 | 0.81 | RAB9A (0.39) | SMN1; SMN2HTTCETPPOLB | |
| SCHEMBL7605187 | 0.78 | FDPS (0.45) | LMNAHTT | |
| SCHEMBL7607667 | 0.76 | LMNA (0.40) | SMN1; SMN2LMNAHTTCETPBLM | |
| SCHEMBL8059131 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAHTTCETPBLM | |
| SCHEMBL7605890 | 0.74 | HDAC1 (0.38) | SMN1; SMN2CETPCHRM2 | |
| SCHEMBL7772647 | 0.74 | HPGD (0.46) | CETP | |
| SCHEMBL7605208 | 0.73 | ALDH1A1 (0.34) | SMN1; SMN2LMNACETPPOLB | |
| SCHEMBL7604569 | 0.73 | PTPN1 (0.47) | SMN1; SMN2LMNAHTTCETPCYP2D6 | |
| SCHEMBL7613491 | 0.73 | ACP3 (0.44) | — | |
| SCHEMBL7926683 | 0.72 | CETP (0.37) | SMN1; SMN2LMNAHTTCETPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | disclosed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |